$40.89
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
IDEAYA Biosciences
IDYANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
IDEAYA Biosciences (NASDAQ:IDYA) Stock, Analyst Ratings, Price Targets, Forecasts
IDEAYA Biosciences Inc has a consensus price target of $46.31 based on the ratings of 16 analysts. The high is $69 issued by JP Morgan on July 12, 2024. The low is $24 issued by Baird on November 18, 2022. The 3 most-recent analyst ratings were released by JP Morgan, RBC Capital, and BTIG on July 12, 2024, July 11, 2024, and July 9, 2024, respectively. With an average price target of $64 between JP Morgan, RBC Capital, and BTIG, there's an implied 56.52% upside for IDEAYA Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
RBC Capital
BTIG
Stifel
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for IDEAYA Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/12/2024 | Buy Now | 68.75% | JP Morgan | Anupam Rama | $65 → $69 | Maintains | Overweight | Get Alert |
| 07/11/2024 | Buy Now | 49.18% | RBC Capital | Gregory Renza | $53 → $61 | Maintains | Outperform | Get Alert |
| 07/09/2024 | Buy Now | 51.63% | BTIG | Justin Zelin | $55 → $62 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 54.07% | Stifel | Benjamin Burnett | $63 → $63 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 46.74% | Oppenheimer | Matthew Biegler | $53 → $60 | Maintains | Outperform | Get Alert |
| 07/08/2024 | Buy Now | 22.28% | Mizuho | Graig Suvannavejh | → $50 | Initiates | → Outperform | Get Alert |
| 06/04/2024 | Buy Now | 54.07% | Stifel | Benjamin Burnett | $55 → $63 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 12.5% | Goldman Sachs | Corinne Jenkins | $53 → $46 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 27.17% | Wedbush | Robert Driscoll | → $52 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | Buy Now | 46.74% | Citigroup | Yigal Nochomovitz | $40 → $60 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 34.51% | BTIG | Justin Zelin | → $55 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | 39.4% | JP Morgan | Anupam Rama | $51 → $57 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 29.62% | RBC Capital | Gregory Renza | $43 → $53 | Maintains | Outperform | Get Alert |
| 01/26/2024 | Buy Now | 29.62% | Goldman Sachs | Corinne Jenkins | $36 → $53 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | 29.62% | Goldman Sachs | Corinne Jenkins | $36 → $53 | Maintains | Buy | Get Alert |
| 01/10/2024 | Buy Now | 5.16% | RBC Capital | Gregory Renza | $36 → $43 | Maintains | Outperform | Get Alert |
| 12/06/2023 | Buy Now | -11.96% | RBC Capital | Gregory Renza | → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 0.27% | JP Morgan | Anupam Rama | $35 → $41 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | 5.16% | Wedbush | Robert Driscoll | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | 7.61% | Guggenheim | Vanck Zhu | $48 → $44 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 5.16% | Wedbush | Robert Driscoll | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | -11.96% | RBC Capital | Gregory Renza | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | -21.74% | RBC Capital | Gregory Renza | → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | 5.16% | Wedbush | Robert Driscoll | $40 → $43 | Maintains | Outperform | Get Alert |
| 09/12/2023 | Buy Now | -9.51% | Goldman Sachs | Corinne Jenkins | $31 → $37 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | -21.74% | JP Morgan | Anupam Rama | $28 → $32 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | -21.74% | RBC Capital | Gregory Renza | $30 → $32 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | -2.18% | Wedbush | Robert Driscoll | $35 → $40 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | -14.4% | Oppenheimer | Matthew Biegler | $30 → $35 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | -19.3% | SVB Leerink | Christopher Liu | → $33 | Initiates | → Outperform | Get Alert |
| 05/24/2023 | Buy Now | -21.74% | Goldman Sachs | Corinne Jenkins | → $32 | Initiates | → Buy | Get Alert |
| 04/24/2023 | Buy Now | -2.18% | Guggenheim | Vanck Zhu | $32 → $40 | Maintains | Buy | Get Alert |
| 04/24/2023 | Buy Now | -41.31% | Stifel | Benjamin Burnett | $18 → $24 | Upgrade | Hold → Buy | Get Alert |
| 03/23/2023 | Buy Now | -36.41% | Berenberg | Zhiqiang Shu | → $26 | Initiates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | -21.74% | Guggenheim | Charles Zhu | → $32 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | -38.86% | RBC Capital | Gregory Renza | → $25 | Reiterates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | -38.86% | RBC Capital | Gregory Renza | → $25 | Initiates | → Outperform | Get Alert |
| 12/28/2022 | Buy Now | -29.08% | Capital One | Zegbeh Jallah | → $29 | Initiates | → Overweight | Get Alert |
| 11/18/2022 | Buy Now | -41.31% | Baird | Joel Beatty | $18 → $24 | Maintains | Outperform | Get Alert |
| 10/27/2022 | Buy Now | -36.41% | Citigroup | Yigal Nochomovitz | → $26 | Initiates | → Buy | Get Alert |
| 09/13/2022 | Buy Now | -21.74% | Guggenheim | Charles Zhu | $20 → $32 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | -55.98% | Baird | Joel Beatty | $26 → $18 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | -51.09% | Oppenheimer | Matthew Biegler | $25 → $20 | Maintains | Outperform | Get Alert |
| 08/15/2022 | Buy Now | -68.21% | Stifel | Benjamin Burnett | $16 → $13 | Downgrade | Buy → Hold | Get Alert |
| 03/10/2022 | Buy Now | -51.09% | Stifel | Benjamin Burnett | $27 → $20 | Upgrade | Hold → Buy | Get Alert |
| 09/23/2021 | Buy Now | -33.97% | Stifel | Benjamin Burnett | — | Initiates | → Hold | Get Alert |
| 08/11/2021 | Buy Now | -26.63% | HC Wainwright & Co. | Edward White | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for IDEAYA Biosciences (IDYA) stock?
The latest price target for IDEAYA Biosciences (NASDAQ:IDYA) was reported by JP Morgan on July 12, 2024. The analyst firm set a price target for $69.00 expecting IDYA to rise to within 12 months (a possible 68.75% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEAYA Biosciences (IDYA)?
The latest analyst rating for IDEAYA Biosciences (NASDAQ:IDYA) was provided by JP Morgan, and IDEAYA Biosciences maintained their overweight rating.
When was the last upgrade for IDEAYA Biosciences (IDYA)?
The last upgrade for IDEAYA Biosciences Inc happened on April 24, 2023 when Stifel raised their price target to $24. Stifel previously had a hold for IDEAYA Biosciences Inc.
When was the last downgrade for IDEAYA Biosciences (IDYA)?
The last downgrade for IDEAYA Biosciences Inc happened on August 15, 2022 when Stifel changed their price target from $16 to $13 for IDEAYA Biosciences Inc.
When is the next analyst rating going to be posted or updated for IDEAYA Biosciences (IDYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEAYA Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEAYA Biosciences was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.
Is the Analyst Rating IDEAYA Biosciences (IDYA) correct?
While ratings are subjective and will change, the latest IDEAYA Biosciences (IDYA) rating was a maintained with a price target of $65.00 to $69.00. The current price IDEAYA Biosciences (IDYA) is trading at is $40.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.